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Abstract
As Dobzhansky wrote, nothing in biology makes sense outside the context of the evolutionary
theory, and this truth has not been sufficiently explored yet by medicine. We comment on Shanks
and Pyles' recently published paper, Evolution and medicine: the long reach of "Dr. Darwin", and discuss
some recent advancements in the application of evolutionary theory to carcinogenesis. However,
we disagree with Shanks and Pyles about the usefulness of animal experiments in predicting human
hazards. Based on the darwinian observation of inter-species and inter-individual variation in all
biological functions, Shanks and Pyles suggest that animal experiments cannot be used to identify
hazards to human health. We claim that while the activity of enzymes may vary among individuals
and among species, this does not indicate that critical events in disease processes occurring after
exposure to hazardous agents differ qualitatively between animal models and humans. In addition,
the goal is to avoid human disease whenever possible and with the means that are available at a
given point in time. Epidemics of cancer could have been prevented if experimental data had been
used to reduce human exposures or ban carcinogenic chemicals. We discuss examples.
The paper by Shanks and Pyles [1] correctly summarizes
the contributions of evolutionary biology to medicine,
following several other authors in different fields of med-
icine [2-5]. Carcinogenesis, for example, can be inter-
preted as the consequence of selection of mutated cells
similar to that which, in the theory of evolution, occurs at
the population level. Instead of considering a population
of organisms, we can refer to a population of cells belong-
ing to a multicellular organism. Cancer can be described
as the outcome of mutation and selection. The rapid
change in risk for some cancers after migration from one
population to another suggests that carcinogenesis
involves – in addition to mutations – some late event that
most likely consists in the selection of cells already carry-
ing mutations. To give a couple of examples, in the case of
gastric and liver cancers, exposure to Helicobacter pylori
(stomach cancer) or to hepatitis B or C viruses (liver can-
cer) in childhood would set the risk typical of the areas of
origin, while reduced exposure to cofactors might help to
explain the lower risk in those who migrate to Western
countries. In the case of liver cancer in particular, a reduc-
tion in exposure to aflatoxins is believed to explain reduc-
tion in risk after migration. Cofactors can be interpreted as
"selectogens", i.e. exposures that facilitate selection of
mutated cells (cells previously exposed to "mutagens" or
created by spontaneous replication errors).
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This relatively new paradigm in carcinogenesis can thus be
useful in understanding some observations made by epi-
demiologists, in particular the fact that many human car-
cinogenic exposures – such as hormones or some dietary
constituents – are apparently not mutagenic.
Also, quite relevant to recent developments in the study of
chronic diseases like cancer or cardiovascular disease is
the idea that these are not fixed entities but rather con-
stantly change their microscopic and clinical phenome-
nology, such that myocardial infarction today is a
different entity from what it was 50 years ago, and lung
cancer is now predominantly represented by adenocarci-
nomas instead of squamous cell carcinomas. This is in
line with Darwin's fight against "fixism", or the "typolog-
ical" view that interpreted species as fixed types.
Another consequence of evolutionary change and selec-
tion is that darwinism has induced the development of a
number of powerful tools, in particular mathematical
ones, to describe the competition among species and the
concept of "fitness". "Darwinian dynamics" has become a
very fruitful field of research, with applications in dispa-
rate disciplines from zoology to carcinogenesis [6].
Finally, but this is an incomplete list, therapeutics has at
least in part taken advantage of darwinian concepts when
dealing with resistance to antibiotics or to chemotherapy.
It is perfectly justified to state, as Dobzhansky wrote, that
nothing in biology makes sense outside the context of the
evolutionary theory, and this truth has not been suffi-
ciently explored yet by medicine.
Unfortunately, Shanks and Pyles derive from their dar-
winian approach some considerations relevant to disease
prevention and public health that are not totally war-
ranted. Public health is based on science but is more than
science and involves policy decisions based on incom-
plete data, similarly to clinical medicine. In both, the end
is not knowledge, but rather the well-being of the popula-
tion (or the individual) and equity. Based on the darwin-
ian observation of inter-species and inter-individual
variation in all biological functions, Shanks and Pyles sug-
gest that animal experiments are not very useful in identi-
fying hazards to human health. They note large variations
in response to drugs in both animals and humans, and
call for the development of more individualized
approaches to therapies. This is not particularly new and
is certainly acceptable. However, they apply the same con-
cept to the usefulness of animals in identifying potential
human carcinogens, and here we disagree. The reasons for
disagreement are essentially two-fold. First, prevention
has an ethical component, i.e. the goal is to avoid human
disease whenever possible and with the means that are
available at a given point in time. Epidemics of cancer
have occurred that could have been prevented if experi-
mental data had been used to reduce human exposures or
ban carcinogenic chemicals [7]. There are many reasons
why we cannot rely upon observation in humans: it
implies entails following-up cohorts of exposed subjects
for decades, thus postponing prevention; often the popu-
lations are too small, or difficult to recruit and investigate,
or exposure assessment is too complex. A very clear exam-
ple is 1,3-butadiene, the carcinogenicity of which has
been considered by a Working Group of the IARC Mono-
graphs [8]. More than 20 years ago one of us contributed
to the first experiments showing that this widely used
chemical induced cancers at multiple organ sites in
rodents, including a very high incidence of otherwise
extremely rare cancers (heart hemangiosarcomas). There
was no doubt that the chemical was a potent carcinogen,
given the consistency of the observations, the dose-
response relationship, the unusual type of tumours, and
the very high incidence. After so many years, however, still
we have a limited number of sound epidemiological stud-
ies, given the considerable difficulties encountered in
these kinds of investigations, but the studies are quite con-
sistent with the animal observations.
Another argument against Shanks and Pyles' interpreta-
tion is the extremely successful use of animal experiments
for preventive purposes, as clearly demonstrated by the
history of the IARC Monographs.
Shanks and Pyles note that while humans and rodents
used in biomedical research share numerous genetic sim-
ilarities, allelic differences exist and rodent models used to
evaluate diseases induced in humans typically have less
genetic variability than do human populations. We cer-
tainly agree that the range of human variability due to pol-
ymorphisms at specific genetic loci cannot be captured
from studies in animals of limited genetic variability.
However, this limitation does not mean that rodents are
not useful or relevant to the evaluation of diseases, such as
cancer, in humans. For the most part, differences in how
laboratory animals and humans metabolize environmen-
tal agents, or in the interactions of these agents with
molecular targets (e.g., DNA, enzymes, or nuclear recep-
tors), are quantitative in nature. For example, cytochrome
P450 2E1, which is present in animals and humans, acti-
vates numerous environmental agents [9], including the
known human carcinogens vinyl chloride and 1,3-butadi-
ene, to DNA-reactive alkylating agents. While the activity
of this enzyme and other metabolizing enzymes may vary
among individuals, this does not indicate that critical
events in disease processes occurring after exposure to
hazardous agents differ qualitatively in animals and
humans. Similarly, the human carcinogen, diethyl-
stilbestrol (DES), activates estrogen receptor in animals
and in humans.Philosophy, Ethics, and Humanities in Medicine 2008, 3:6 http://www.peh-med.com/content/3/1/6
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Shanks and Pyles, while critical of the use of experimenta-
tion on animals to predict human health hazards, offer no
alternative approach to indentifying environmental or
occupational carcinogens and to formulating strategies to
eliminate or reduce human exposures. Waiting for high
incidences of human cancers, which may take 30 or more
years from the time of first exposure to clinical manifesta-
tion of disease, is not an acceptable method for identify-
ing human carcinogens. For several agents that were
shown to be carcinogenic in animals, human carcino-
genicity was later confirmed when reliable epidemiologi-
cal data became available, e.g., 1,3-butadiene, cadmium,
diethylstilbestrol, formaldehyde, ethylene oxide, and
vinyl chloride [7]. We believe it to be irresponsible to
ignore health effects data derived from animal studies.
Public health protective strategies are needed to avoid
repeating mistakes of the past similar to that of the DES
tragedy in which adverse health effects in animals were
ignored and human use of this drug not banned until
1971, after the discovery of high rates of rare, clear-cell
adenocarcinomas of the vagina and cervix in DES-exposed
daughters [10].
Although precise quantification of the effectiveness of
cancer prevention programs is extremely difficult, public
health is best served when primary prevention actions are
taken based on adverse health effects identified in studies
in animals or in humans. Trans species extrapolations of
health risks could be improved with increased informa-
tion on the range and distribution of factors affecting
responses in human populations. While no animal model
will allow a precise estimation of cancer risk in all
humans, Shanks and Pyles contend that laboratory ani-
mals are not useful models for evaluating potential
human carcinogenicity. This view is contrary to that of all
major public health agencies, including the International
Agency for Research on Cancer [11], the US National Tox-
icology Program [12], and the US Environmental Agency
[13], which have adopted the perspective that even in the
absence of carcinogenicity data in humans, it is biologi-
cally plausible that agents for which there is sufficient evi-
dence of carcinogenicity in experimental animals pose a
carcinogenic risk to humans. This view is based largely on
the fact that all known human carcinogens that have been
studied adequately in experimental animals produce pos-
itive carcinogenic results [12]. For chemicals that are con-
sidered to be possible or probable human carcinogens
based on animal data and/or mechanistic data, insuffi-
cient data are available from exposed human populations
to make definitive determinations of causal relationships.
In spite of some disagreements, darwinian medicine can
certainly contribute to a greater understanding of the role
of genetic variability or gene expression differences in
dose-response relationships across species and among
susceptible subpopulations.
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